报告题目：Development of Novel Nucleic Acid Drug Delivery Systems Based on Nanotechnology and Exosome Technology
报告时间：2017年6月23日（周五）10:30-12:00
报告地点：南校区.第三教学楼107教室
报 告 人：高仓喜信（日本京都大学药学部教授，日本DDS学会理事长）
主 持 人：方 亮 教授
主办单位：国际交流处
药学院
无涯学院
研究生处（学科建设办公室）
辽宁省研究生现代药物领域创新与交流中心
报告人简介：
高仓喜信(Yoshinobu Takakura)，男，京都大学药学部·药学研究科病态情报药学分野教授。1987年毕业于京都大学并取得博士学位后留校任教，1989年作为访问学者留学美国堪萨斯大学，2014年4月-2016年3月任京都大学药学部部长，药学研究科科长。现任日本DDS学会理事长，日本药剂学会常务理事，日本药物动态学会评议员。发表原著论文289篇，参与著书47本。其他学术兼职有：
日本DDS学会机关志Drug Delivery System，编集委员长
Advanced Drug Delivery Reviews (2006-2011),执行编委
European Journal of Pharmaceutical Sciences (2002-)，编委
Drug Metabolism and Pharmacokinetics (2002-)，编委
Biological and Pharmaceutical Bulletin (1999-2003)，编委
Journal of Biochemistry (2000-)，顾问
Pharmaceutical Research (2001-)，顾问
报告内容简介：
Yoshinobu Takakura, Ph.D.
Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto, 606-8501, Japan.
A variety of nucleic acid drugs have been studied as promising drug candidates for the treatment of a wide range of diseases, including cancer, viral diseases and other incurable diseases. For a successful therapy with these nucleic acid drugs, it is important to establish a rational strategy for the design and delivery of the nucleic acid drugs. We have been studying on the development of novel nucleic acid drug delivery systems in order to optimize the nucleic acid drug-based therapies. Among nucleic acid drugs, synthetic DNA containing unmethylated cytosine-phosphate-guanine (CpG) dinucleotides (CpG DNA), which is recognized by Toll-like receptor 9 (TLR9) expressed by mammalian immune cells, has attracted a lot of attention as a promising adjuvant for the treatment of various diseases because of its immunostimulatory activity. I will focus on the recent results on the development of delivery systems for CpG DNA in my laboratory. Following two topics will be included, 1) CpG DNA Delivery Based on Polypod-like Structured DNA, POLYPODNA (Polypod-like structured nucleic acid), 2) Exosome-Based CpG DNA Delivery.
